GRAIL Hit by Securities Lawsuit After NHS-Galleri Trial Failure

What happened

GRAIL's stock lost $2.2B on February 20 after disappointing NHS-Galleri trial results. A securities class action now seeks to represent investors who bought between May 2025 and February 2026. The trial failure is a major setback for Galleri's PMA pathway and reimbursement prospects. GRAIL's financials show ongoing losses and cash burn, making this binary outcome critical. The lawsuit adds legal overhang to an already uncertain outlook.

Implication

The NHS-Galleri failure invalidates the primary value driver for GRAIL. With PMA now unlikely and reimbursement stalled, the stock faces prolonged downside. The class action creates legal risk. Cash burn continues with no immediate revenue catalyst. We recommend selling shares given the deteriorated fundamental picture.

Thesis delta

The previous hold thesis relied on positive NHS-Galleri results to de-risk the PMA pathway. The trial failure eliminates that possibility, shifting risk/reward decisively to the downside. We downgrade from Hold to Sell.